ReNeuron enters grant-funded collaboration with University of Cardiff
Francesca Morgan
Company News - 2 mins
12:38, 14th August 2019

Clinical-stage stem cell business, ReNeuron Group (RENE) FOLLOW, announced on Wednesday that it had entered a grant-funded collaboration with the University of Cardiff. 

The collaboration will utilise AIM-listed ReNeuron’s exosome-based drug delivery technology platform. 

The grant was awarded under Innovate UK’s Knowledge Transfer Partnership, a government-funded scheme which encourages partnerships between businesses and universities in the UK to spark innovation and growth.

As part of the scheme, Innovate UK will fund a £250,000 collaborative programme of research to be undertaken by ReNeuron and the European Cancer Stem Cell Research Institute at Cardiff University.

The research programme will use ReNeuron's CTX stem cell-derived exosomes to develop novel systems to enable the delivery of therapeutic nucleic acids.

Exosomes are considered an integral tool for drug delivery to the scientist because the way in which cell-to-cell communication takes place occurs via exosomes. 

Thus, under certain conditions, exosomes produced by stem cells can be manipulated to carry different cargos so that therapeutic molecules can be loaded for delivery to specific tissues within the body.

ReNeuron intends to utilise its technology platform to target the exosomes travelling to the brain. Dr Randolph Corteling, Head of Research at ReNeuron, commented: 

“We are very excited about the potential of our exosome technology platform to deliver therapeutic compounds to the brain and thereby to make a real step-change in the development of treatments against hard-to-target disorders of the central nervous system."

A common concern for scientists is getting those therapeutic agents across the blood barrier, the company explained -- and whilst this has remained a widespread significant challenge, data generated at ReNeuron has already demonstrated the ability of its CTX exosomes to cross the blood barrier.

Thus, the collaboration between the group and university will build on this challenge, focusing on opening up a new route for the delivery of therapeutic agents that have previously failed to target the brain. 

For more News & Updates on ReNeuron Group: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles